TC
SAGE icon

Truvestments Capital’s Sage Therapeutics SAGE Stock Holding History

Truvestments Capital’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-39
Closed -$356 – 1107
2025
Q2 		$356 Hold
39
– – ﹤0.01% 912
2025
Q1 		$310 Hold
39
– – ﹤0.01% 977
2024
Q4 		$212 Hold
39
– – ﹤0.01% 973
2024
Q3 		$282 Buy
+39
New +$357 ﹤0.01% 893
2024
Q2 		– Sell
-39
Closed -$731 – 596
2024
Q1 		$731 Hold
39
– – ﹤0.01% 661
2023
Q4 		$845 Hold
39
– – ﹤0.01% 719
2023
Q3 		$803 Hold
39
– – ﹤0.01% 634
2023
Q2 		$1.83K Hold
39
– – ﹤0.01% 604
2023
Q1 		$1.64K Hold
39
– – ﹤0.01% 589
2022
Q4 		$1.49K Hold
39
– – ﹤0.01% 778
2022
Q3 		$2K Hold
39
– – ﹤0.01% 568
2022
Q2 		$1K Buy
+39
New +$1.31K ﹤0.01% 617
2022
Q1 		– Sell
-39
Closed -$2K – 467
2021
Q4 		$2K Hold
39
– – ﹤0.01% 556
2021
Q3 		$2K Hold
39
– – ﹤0.01% 548
2021
Q2 		$2K Hold
39
– – ﹤0.01% 558
2021
Q1 		$3K Buy
+39
New +$3.2K ﹤0.01% 579

Other funds holding SAGE

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Truvestments Capital's SAGE Position: Q3 2025 in Review

Truvestments Capital sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 39 shares — an estimated $356 sold.

Truvestments Capital first reported a position in SAGE in Q1 2021 and held it in 16 quarters. The position peaked at $3K in Q1 2021. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.

  • Truvestments Capital reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Truvestments Capital sold 39 Sage Therapeutics shares in Q3 2025, an estimated $356.
  • Truvestments Capital first reported a position in Sage Therapeutics in Q1 2021 and held it in 16 quarters.
  • Truvestments Capital's Sage Therapeutics position peaked at $3K in Q1 2021.
  • 5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.

Based on Truvestments Capital's 13F filing for Q3 2025, filed 14 Nov 2025.